{"id":"W2030714208","doi":"10.1038/pcan.2014.24","title":"An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study","year":2014,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Bicalutamide; Medicine; Discontinuation; Antiandrogen; Urology; Prostate cancer; Clinical endpoint; Androgen; Internal medicine; Androgen deprivation therapy; Goserelin; Randomized controlled trial; Cancer; Androgen receptor; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007626451,0.0002303506,0.0005370872,0.0004142382,0.0002120071,0.0001664109,0.0001385863,0.00006490594,0.00004976556],"category_scores_gemma":[0.0002033965,0.0001747985,0.00001177605,0.0005185385,0.0003581394,0.0003115429,0.00006874261,0.0002204109,0.000001478391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002264348,"about_ca_system_score_gemma":0.001514172,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.07609087,"about_ca_topic_score_gemma":0.1457094,"domain_scores_codex":[0.9972876,0.0004796843,0.0004542044,0.0007026801,0.0005047967,0.0005710371],"domain_scores_gemma":[0.9980275,0.0002919048,0.00009903621,0.0003615729,0.0003348963,0.0008850792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5083429,0.006440314,0.4020129,0.000565359,0.0003198596,0.0003014098,0.01494633,0.00002871825,0.006769098,0.0002195824,0.0008383781,0.05921514],"study_design_scores_gemma":[0.3701447,0.04597978,0.5692475,0.0005870544,0.0005724329,0.000006055172,0.006070987,0.001804458,0.0006621946,0.002489019,0.001841895,0.0005939532],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987459,0.001343955,0.000008915958,0.002207986,0.00003999821,0.007712737,0.0008150793,0.00001696952,0.000395371],"genre_scores_gemma":[0.9966635,0.0004257363,0.0002341578,0.0001563263,0.00006927567,0.001763573,0.0002920926,0.00003456499,0.0003608385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1672346,"threshold_uncertainty_score":0.9300615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06466855488777716,"score_gpt":0.4243131971048261,"score_spread":0.3596446422170489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}